Tag: Brazil health regulator

Insights

ANS Excludes Hapvida From Calculation and Caps Health Plan Increase at 5.11%

29 de May de 2026
Insights

Anvisa Reviews Elevidys, a R$20 Million Gene Therapy Suspended in Brazil

29 de April de 2026

The most comprehensive resource for portfolio managers and investors focused on emerging markets — with a special emphasis on Brazil. In-depth analysis, curated insights, and data-driven perspectives on Latin America’s largest economy.

Navigate

Home
About us
Insights
Compliance
Contact

Follow

X
Instagram
LinkedIn
Facebook

Tag: Brazil health regulator

ANS Excludes Hapvida From Calculation and Caps Health Plan Increase at 5.11%

Anvisa Reviews Elevidys, a R$20 Million Gene Therapy Suspended in Brazil